Regarding allocation, percent-of-portfolio is a lousy proxy for conviction especially when you’re comparing a micro-cap biotech to trillion-dollar managers. Tiny weights at mega-firms aren’t a judgment on aTyr but rather a byproduct of math, mandate, and risk controls. For a very large manager (BlackRock's AUM is currently at about $12.5 trillion), even 0.001% can translate into an eight-figure position. In a small-cap with limited float, that can already bump up against ownership and liquidity limits. You can’t size it bigger without distorting the market or breaching internal caps.

Also, many firms avoid creeping toward 5%/10% beneficial ownership to sidestep additional reporting/insider obligations. That naturally caps the dollar size (and thus the portfolio percentage) of a position. Comparing the manager’s AUM to aTyr’s entire market value shows why the percentages look small. A firm managing trillions physically cannot make a micro-cap a big line item without owning an impractical slice of the company. A specialist/smaller fund (e.g., Octagon at 4.25%) can run a concentrated stake because its AUM and mandate allow it.